Pharma BD Deal Intelligence
A $1.1B all-cash bet on a single Parkinson's asset that took nine years, two FDA rejections, and a second Complete Response Letter to reach any approval—finally clearing only in the EU in April 2026, after AbbVie's competing infusion had already beaten it to every major market by one to three years.
Nine years after paying $1.1B for a single Parkinson's asset, the drug still had no US approval, had taken two FDA rejections, and had already been beaten to market by a direct competitor.
Full analysis, sources & comparables →Mitsubishi Tanabe agreed to acquire NeuroDerm for $1.1B in cash at $39/share, a 79% premium over the unaffected price, betting on ND0612 as a less-invasive…
Viceroy Research argued that the $1.1B NeuroDerm acquisition would be value-destructive, predicting a complete write-off of NeuroDerm's ~$970M enterprise value…
FDA issued a Complete Response Letter for ND0612 in June 2024 citing facility-related concerns rather than clinical issues, delaying market entry roughly seven…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Mitsubishi Tanabe agreed to acquire NeuroDerm for $39.00/share in cash, total transaction value approximately $1.1B (79% premium over June 9 unaffected price). NeuroDerm's lead asset ND0612 is a late-stage continuous subcutaneous levodopa/carbidopa formulation for Parkinson's disease motor fluctuations, with peak sales potential of ~$1.7B. Largest Japan-Israel pharma deal at the time.
Nine years after paying $1.1B for a single Parkinson's asset, the drug still had no US approval, had taken two FDA rejections, and had already been beaten to market by a direct competitor.
Assessment window: 5yr post-close.
90K US cases/yr · $1.9B US PD treatment market 2024 · ~$1.7B ND0612 peak sales potential cited at deal time
Parkinson's disease patients on long-term oral levodopa progressively develop motor fluctuations — predictable wearing-off and unpredictable ON/OFF cycles — driven by levodopa's short plasma half-life and pulsatile dopaminergic stimulation. Continuous-delivery formulations aim to smooth plasma exposure, reduce OFF-time, and avoid the surgical complexity of intestinal infusion.
ND0612 enters a motor-fluctuation segment defined by trade-offs between efficacy, invasiveness and convenience. AbbVie's Duopa (intestinal levodopa-carbidopa gel) requires PEG-J tube placement and dominates advanced-PD share but limits adoption due to surgical burden; AbbVie's Vyalev (foscarbidopa/foslevodopa, FDA-approved Oct 2024) was the first 24-hour SC infusion of a levodopa pro-drug and is ND0612's most direct competitor. Oral extended-release formulations — Amneal's Rytary and Crexont (approved Aug 2024) — extend dose intervals but cannot match continuous delivery. Deep-brain stimulation remains an option for refractory cases. ND0612 differentiates as a non-prodrug 24-hour subcutaneous CD/LD infusion via a small body-worn pump (BioPharma Dive: https://www.biopharmadive.com/news/mitsubishi-tanabe-to-acquire-neuroderm-for-11b/447731/). Mitsubishi Tanabe paid a 79% premium over the unaffected price for what it positioned as the largest Japan-Israel pharma deal at the time. After a June 2024 CRL, FDA accepted the NDA resubmission in May 2025 with a Q4 2025 PDUFA date — the asset has not yet reached the market more than eight years post-deal.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mitsubishi Tanabe Pharma Corporation / NeuroDerm Ltd. (this deal) | 2017 | $1.1B | 36 |
| Mitsubishi Tanabe Pharma Corporation / GV20 Therapeutics | 2025 | — | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
← Browse all deals · How we score deals
More: 2017 deals · Neurology deals